Traders sold shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on strength during trading on Friday. $41.84 million flowed into the stock on the tick-up and $85.27 million flowed out of the stock on the tick-down, for a money net flow of $43.43 million out of the stock. Of all equities tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $1.08 for the day and closed at $124.42

ALXN has been the topic of several recent research reports. Morgan Stanley restated an “overweight” rating on shares of Alexion Pharmaceuticals in a report on Wednesday, June 29th. Citigroup Inc. raised Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $154.00 price objective on the stock in a research report on Monday, June 27th. Vetr downgraded Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $161.67 price objective on the stock. in a research report on Monday, April 4th. Leerink Swann reaffirmed an “outperform” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, April 10th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $212.00 price objective on shares of Alexion Pharmaceuticals in a research report on Tuesday, April 5th. Eight analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $193.07.

The stock has a market capitalization of $27.87 billion and a PE ratio of 188.23. The stock has a 50-day moving average of $132.82 and a 200 day moving average of $145.76.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.13 by $0.02. The company earned $701 million during the quarter, compared to analysts’ expectations of $710.98 million. The company’s revenue for the quarter was up 16.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.28 EPS. On average, equities analysts anticipate that Alexion Pharmaceuticals Inc. will post $5.06 EPS for the current year.

In related news, EVP John B. Moriarty sold 918 shares of the business’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the completion of the transaction, the executive vice president now directly owns 51,360 shares of the company’s stock, valued at approximately $6,970,579.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Martin Mackay sold 4,097 shares of the business’s stock in a transaction on Monday, May 16th. The stock was sold at an average price of $139.20, for a total value of $570,302.40. Following the transaction, the executive vice president now directly owns 42,706 shares of the company’s stock, valued at $5,944,675.20. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently added to or reduced their stakes in ALXN. Wetherby Asset Management Inc. boosted its position in Alexion Pharmaceuticals by 0.5% in the fourth quarter. Wetherby Asset Management Inc. now owns 10,211 shares of the biopharmaceutical company’s stock valued at $1,948,000 after buying an additional 49 shares during the last quarter. LS Investment Advisors LLC boosted its position in Alexion Pharmaceuticals by 1.7% in the fourth quarter. LS Investment Advisors LLC now owns 5,257 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 89 shares during the last quarter. Mutual of America Capital Management LLC boosted its position in Alexion Pharmaceuticals by 0.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 25,147 shares of the biopharmaceutical company’s stock valued at $4,797,000 after buying an additional 118 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Alexion Pharmaceuticals by 1.3% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,722 shares of the biopharmaceutical company’s stock valued at $2,808,000 after buying an additional 192 shares during the last quarter. Finally, RidgeWorth Capital Management LLC boosted its position in Alexion Pharmaceuticals by 0.3% in the fourth quarter. RidgeWorth Capital Management LLC now owns 150,951 shares of the biopharmaceutical company’s stock valued at $28,794,000 after buying an additional 379 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.